Default company panoramic image
E1cf24cb 140d 4b4f a18e 8437ddccec0a

Oxtox Ltd

A handheld reader and disposable sensors for screening drugs of abuse in saliva. The product tests for THC in cannabis and methamphetamines. Drugsensor is u...

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Stockport, England, GB
  • Currency GBP
  • Founded June 2006
  • Employees 14
  • Website oxtox.com

Company Summary

A handheld reader and disposable sensors for screening drugs of abuse in saliva. The product tests for THC in cannabis and methamphetamines. Drugsensor is up to 10 times faster than products used by the Police and in the workplace. Customer testing starts April-14. We anticipate first sales in Q4, 2014. The company is raising £1.0M from its existing Investors and seeks £200k to bring the product to market and produce first customer sales.

Team

  • Default avatar
    Michael Penington
    Dr

    Michael Penington (Chairman) is an angel investor in Oxtox, and owns 7.4% of the company. He was an investment banker with Morgan Stanley for 16 years to 2000. Subsequently he has been an investor in early stage technology businesses. Since 2008 he has been a partner in a venture capital firm (Longwall Venture Partners) with some £70 million under management. He has a non-executive role at Oxtox.

  • Default avatar
    Dennis Camilleri
    Mr

    Dennis Camilleri (CEO) is a business development executive with over 30 years of experience in managing multi-disciplinary teams in high-tech companies including Melles Griot, Willett, Rapid Biosensors Systems and Leica Microsystems. He has consulted for Investor Groups Fusion IP and Imperial Innovations in spin-out company development and commercialisation of research. After graduating in Physics, and with an MSc in Applied Optics, he was elec

  • Default avatar
    Murdo Black
    Dr

    Murdo Black (CTO) is a scientist with over 25 years of experience developing in vitro diagnostic products. He was initially at Medisense, prior to launch of the first biosensor. Subsequently he was R&D Director at both Hypoguard and Axis-Shield. He has patents in membrane technology, biosensor design, chemistry and biomarker development.